Abstract
Prostate cancer is the most common male cancer and one of the most common causes of cancer death among men in European countries. In the last years, a large number of new drugs for treatment of castration-resistant prostate cancer (CRPC) have been approved, others are still in an advanced stage of clinical testing. In this review, we provide an overview on new substances which act via modulation or inhibition of angiogenesis. Results and limitations from clinical studies as well as future needs for improvement of those agents in CRPC are critically discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
